儿童心脏移植后依维莫司联合低剂量他克莫司:一项随机临床试验
该多中心随机开放标签临床试验纳入211例儿童心脏移植后存活6个月的患者,随机接受依维莫司联合低剂量他克莫司(n=107)或标准剂量他克莫司联合吗替麦考酚酯(n=104)治疗30个月。结果显示两组MATE-3评分无显著差异(均差-0.32,95%CI -0.90至0.20,P=0.16),MATE-6评分依维莫司组不高于吗替麦考酚酯组(基线校正均差-0.40,95%CI -1.81至0.93),满足安全性成功标准。依维莫司组12个月时估算肾小球滤过率改善更明显(均差10.5 mL/min/1.73 m2,95%CI 1.09-19.91),CMV感染发生率更低(HR 0.50,95%CI 0.26-0.93)。
要点
- 依维莫司联合低剂量他克莫司与标准剂量他克莫司联合吗替麦考酚酯在30个月MATE-3评分上无显著差异。
- 依维莫司组MATE-6评分不高于吗替麦考酚酯组,满足安全性成功标准(非劣效界值<3)。
- 依维莫司组12个月eGFR改善更明显(均差10.5 mL/min/1.73 m2,95%CI 1.09-19.91),CMV感染发生率更低(HR 0.50,95%CI 0.26-0.93)。
核心结论
- 在儿童心脏移植后存活6个月的患者中,依维莫司联合低剂量他克莫司与他克莫司联合吗替麦考酚酯在预防细胞性排斥、CAV和CKD复合终点方面30个月时无差异。
- 依维莫司联合低剂量他克莫司基于6种MATE总负担似乎是安全的,并可能与肾功能改善和CMV感染减少相关。
研究设计与样本
- 多中心、随机、开放标签临床试验,纳入2018年2月至2020年8月在美国25个中心入组的211例儿童心脏移植后存活6个月的患者。
- 参与者随机接受依维莫司联合低剂量他克莫司(n=107)或标准剂量他克莫司联合吗替麦考酚酯(n=104)治疗30个月,末次随访日期为2023年4月17日。
主要发现
- 30个月时平均MATE-3评分两组无差异(均差-0.32,95%CI -0.90至0.20,P=0.16)。
- 依维莫司组平均MATE-6评分不高于吗替麦考酚酯组(基线校正均差-0.40,95%CI -1.81至0.93),满足安全性成功标准(非劣效界值<3)。
- 移植物存活、无MATE生存或免于任何单个MATE方面无差异。
- 依维莫司组12个月时eGFR改善更明显(均差10.5 mL/min/1.73 m2,95%CI 1.09-19.91)。
- 依维莫司组CMV感染发生率更低(HR 0.50,95%CI 0.26-0.93)。
关键数值与推荐
- 主要疗效终点为30个月时MATE-3评分,一种验证的复合有序终点,包括急性细胞性排斥、CAV和CKD。
- 主要安全性终点为MATE-6评分,涵盖MATE-3评分加上抗体介导的排斥、感染和移植后淋巴增殖性疾病。
- 安全性成功标准为非劣效界值<3。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Studies suggest that everolimus may reduce the risk of rejection, cardiac allograft vasculopathy (CAV), chronic kidney disease (CKD), and cytomegalovirus (CMV) after heart transplant. Everolimus use is controversial because of data demonstrating higher infection deaths when everolimus is introduced de novo after transplant. It is unclear whether everolimus is safe and effective when initiated at 6 months posttransplant in children, a population in which median graft survival is limited to 15 years and randomized clinical trials are lacking. OBJECTIVE: To evaluate the safety and efficacy of everolimus combined with low-dose tacrolimus to prevent major adverse transplant events (MATEs) in children after heart transplant. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, open-label, clinical trial enrolling 211 patients who were alive 6 months after pediatric heart transplant at 25 US sites from February 2018 to August 2020. The last date of follow-up was April 17, 2023. INTERVENTIONS: Participants were randomized to receive everolimus and low-dose tacrolimus (n = 107) or standard-dose tacrolimus and mycophenolate mofetil (n = 104) for 30 months. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the MATE-3 score at 30 months, a validated composite ordinal end point including acute cellular rejection, CAV, and CKD. The primary safety end point was the MATE-6 score, encompassing the MATE-3 score plus antibody-mediated rejection, infection, and posttransplant lymphoproliferative disorder. RESULTS: Among 211 children randomized, the mean age was 8.2 (SD, 6.3) years, 97 (46%) underwent transplant for congenital heart disease, and 49 (23%) were treated for rejection before 6 months. At 30 months, the mean MATE-3 score did not differ between the 2 treatment groups (mean difference, -0.32; 95% CI, -0.90 to 0.20; P = .16). The mean MATE-6 score was no higher in the everolimus group than in the mycophenolate group (baseline-adjusted mean difference, -0.40; 95% CI, -1.81 to 0.93), meeting the success criterion for safety (noninferiority margin <3). There were no differences in graft survival, MATE-free survival, or freedom from any individual MATE. Everolimus was associated with greater improvement in estimated glomerular filtration rate at 12 months (mean difference, 10.5 mL/min/1.73 m2; 95% CI, 1.09-19.91 mL/min/1.73 m2) and a lower incidence of CMV infection (hazard ratio, 0.50; 95% CI, 0.26-0.93). CONCLUSIONS AND RELEVANCE: Among 6-month pediatric heart transplant survivors, everolimus and low-dose tacrolimus did not differ from tacrolimus and mycophenolate in preventing the composite of cellular rejection, CAV, and CKD at 30 months. However, everolimus and low-dose tacrolimus appear to be safe based on the total burden of 6 MATEs and may be associated with improved kidney function and less CMV infection. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03386539.
引用
- Almond CS, Daly KP, Albers EL, et al. Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial. JAMA. 2025. PMID: 40960806. doi:10.1001/jama.2025.14338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。